AI breast cancer risk prediction goes direct-to-consumer amid regulatory uncertainty

A startup is marketing an AI-based breast cancer risk prediction algorithm directly to patients, bypassing traditional clinical channels. The move occurs under a regulatory cloud, with Utah's sandbox program facing scrutiny. This signals a shift toward consumer-driven AI diagnostics, raising questions about validation and oversight.